A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 282 participants.
Also called NCT05564039
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 282 participants
- Sponsor
- Registry
-
NCT05564039
-
- Other papers using this trial's data
- Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Belgium, Germany, Mexico, Romania
- Registry status
- Completed
Technical summary
Registry record NCT05564039. Randomized; no masking; primary purpose treatment. Start 2022-11-30 (actual); primary completion 2024-07-15 (actual). Results posted on 2025-08-03.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)
- Acronym
- SURPASS-SWITCH
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Tirzepatide
- Intervention (Drug)
- Dulaglutide
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct05564039- Content hash
6a6e2a06caff82de9386cf44a63463d483e3e94a13b1154e1da0a568efd267b9